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A B S T R A C T
Surveillance and management of livestock diseases is often evaluated with reference to expected sector-wide
costs. In contrast, we calculate losses or savings for individual herd owners of a change in monitoring strategy
during a national cattle disease eradication programme: bovine viral diarrhoea (BVD) in Ireland. The alternative
strategy differs in how the disease is identified; by its sample- rather than census-based approach; and by its
greater cost per test. We examined the costs faced by each breeding herd if testing were conducted using serology
on a sample of young stock, in contrast to the current method of tissue-tag testing of all newborn calves.
Following best knowledge of the likely costs, the following input values were used: i) €2.50 per test for tissue-tag
testing and €7.66 for serology, ii) serology conducted on a sample of 10 young stock per management group
from either the 6–12 month or 9–18 month cohorts; iii) 3 scenarios for the number of management groups: one
per herd (M∞), one per 100 cows (M100) and one per 50 cows (M50). We found that many herds would often
not be able to supply a suitable sample of young stock for serology or would face higher testing costs than when
using tissue tag testing. The largest number (25%) of herds would benefit from participating in the change if
sampling were done in October. These could annually save between €2.1 million under M∞ and €0.8 million
under M50 (€108 - €49 per herd). However, analysing herd-level data we found that 90% of all Irish breeding
herds would save less than €1.42 per cow or €99 in total per annum under M∞, and €0.59 per cow or €36 in
total under M50. In a sensitivity analysis, we allowed serology costs to vary between €2 and €10 per animal.
Herds at the 10 t h percentile of most savings made from switching would save at most €155 (M∞ at €2 per
serology test) but would not save anything under M50 at costs ≥ €10. We conclude that, under these as-
sumptions, the expected reduction in testing costs for the majority of beneficiaries would barely outweigh the
practical implications of the strategy switch or the risks to the eradication programme associated with sample
based surveillance. This study does not assess the cost-effectiveness of alternatives post-eradication.
1. Introduction
Considerable costs have been associated with bovine viral diarrhoea
(BVD) (Lindberg and Houe, 2005; Stott et al., 2010; Barrett et al., 2011;
Richter et al., 2017), which is endemic in many countries. Control is
achieved through identification and slaughter of animals persistently
infected (PI) with BVD virus (BVDv), which are the main drivers of
transmission (Lindberg and Houe, 2005; Lindberg et al., 2006; Lanyon
et al., 2013). This method has been the cornerstone of eradication
programmes in a number of countries (Rossmanith et al., 2010; Presi
et al., 2011; Ståhl and Alenius, 2012; Graham et al., 2014; Laureyns,
2014; Nagy et al., 2014; Norström et al., 2014).
Surveillance to identify PIs is based on one of two general methods –
tissue tag testing to detect the presence of the virus or serology to detect
viral antibodies. In the Republic of Ireland (‘Ireland’), a national era-
dication programme was initiated in 2012, and testing was made
compulsory from 2013 onwards (Anon, 2012, 2014; Graham et al.,
2014). It has been based on tissue-tag testing of all newborn calves,
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with samples collected and submitted by herd-owners, and is similar to
that previously implemented in Switzerland and Germany (Ståhl and
Alenius, 2012). It has resulted in a marked reduction in the number of
calves considered to be PI, from 0.77%, in 2013, to only 0.12%, for the
year to 20th December 2017. The programme assigns a negative herd
status (NHS) to a herd if the following three conditions are met: i)
tissue-tag testing for a minimum of three years; ii) a negative BVDv
status for all animals in the herd (assigned directly on the basis of the
animal itself having been tested, or indirectly on the basis of it having
been the dam of one or more test-negative calves); and iii) no PI ani-
mals found within the herd during the previous 12 months. By July
2017 approximately 69,000 of 80,000 breeding herds had achieved
NHS status (Anon, 2017). The aim of the programme is to achieve
eradication of BVDv in the shortest possible time.
Decisions on the management of the programme are taken by a BVD
Implementation Group (BVDIG). As more and more herds obtain NHS
status, the BVDIG has been considering alternative pre-eradication
options for these herds. In particular, the introduction of serological
surveillance was suggested for NHS herds through the sample-based
screening of homebred young stock, known as young stock check
testing. This approach, in addition to testing of milk samples in dairy
herds, has been the basis of the successful eradication programmes in
the Scandinavian countries (Lindberg and Alenius, 1999; Houe et al.,
2006; Løken and Nyberg, 2013). The conceptual basis of such ser-
ological testing is that any PI animal present in a given management
group will transmit infection to the majority of other cattle in the group
within a relatively short period of time. This has been shown experi-
mentally by Sarrazin et al. (2014). Therefore, screening of a limited
number of homebred animals for antibodies to BVDv may provide an
effective means of surveillance. Detection of antibodies would point to
the presence of BVDv in the herd within the lifetime of the animals
sampled. Each separately managed group within the target age range
must be sampled to achieve high herd-level sensitivity (HSe) (Houe
et al., 2006). The required number of samples per group has varied
between different national programmes.
In Ireland, the BVD technical working group (BVDTWG), which
provides scientific information to inform BVDIG decision-making, has
considered the use of serological surveillance (without bulk-milk
testing) during the pre-eradication phase, to consist of sampling 10
young stock (of either sex) from each management group with a cut-
point of two positive test results. This sample size is consequent to re-
questing herd-level sensitivity (HSe) and specificity (HSp) of 99.5% and
100%, respectively (HerdAcc; Jordan and McEwen, 1998). Calculations
assumed a cohort size of 50 animals, a design prevalence of 50% and
individual test sensitivity and specificity of 96.9% and 97.8%, respec-
tively (Guelbenzu Gonzalo, 2015). Animals would be tested when at
least 6 and preferably 9 months of age, in order to prevent false positive
results caused by maternally derived antibodies (MDA, Muñoz-Zanzi
et al., 2000; Sagar, 2003). Additionally, the management group needs
to have been established for a long enough period to allow sufficient
contact between a PI and its fellow cohort animals to achieve the design
seroprevalence on which the sample size is based. On the other hand,
testing of animals older than 18 months of age is usually not re-
commended, as positive test results do not necessarily indicate recent
exposure of the animal to the virus. On the basis of these considera-
tions, testing from amongst the 6–12 month or 9–18 month age range
has been recommended (Pillars and Groom, 2002; Houe 1994; Anon,
2015).
Applying serology in NHS herds would thus require sampling only a
proportion of the young stock in each herd, as opposed to tissue-tag
testing every calf born. Using serology may therefore be a cheaper
option for some herds. However, this would clearly depend on the cost
of each surveillance method. Furthermore, many herds might not be
able to provide a sufficient number of homebred young stock to allow
serology to be used as a surveillance method, particularly if many are
sold in advance of serological testing being carried out.
The usefulness of veterinary interventions in the control of livestock
diseases is often evaluated on the basis of financial costs. This has
usually been done with reference to total costs or average gain or
burden per producer across an entire sector. However, in reality there
are usually important differences in size and production practices
which determine the distribution of costs and benefits amongst pro-
ducers and these may result in a highly skewed distribution of benefits.
This means that total or average values may not be particularly useful
to decision-makers. However, with the growing availability of data at
an individual animal-level this kind of simplification is no longer ne-
cessary.
2. Objectives
With the above considerations in mind, we conducted an analysis to
examine eligibility and potential savings for individual participants
from changes in Ireland’s BVD surveillance strategy. We did this to
inform decision-making on whether reductions in testing costs would
mean that serology should be used as an alternative for surveillance in
NHS herds prior to eradication.
3. Methods
3.1. Data sources, estimates of testing costs and herd type classification
Data for the analysis was drawn from the Irish Government’s
Department of Agriculture, Food and the Marine (DAFM) Animal
Identification and Movement system (AIM) database. We used data for
2015 comprising animal-level information on cattle movements and
birth registrations. Data processing was conducted in Microsoft SQL
Server 2012, SAS 9.3 and Microsoft Excel 2010, and graphical outputs
produced using Microsoft Excel 2010.
To estimate the costs of tissue-tag testing, we calculated the number
of calves born in each herd in 2015 and multiplied this figure by €2.50,
which an investigation by Animal Health Ireland (AHI) had found to be
the most likely testing cost to be faced by NHS herds. Tissue-tag testing
is carried out in designated laboratories (Graham et al., 2014), with
samples from NHS herds typically pooled for screening by real time RT-
PCR.
To compare these costs with serological testing of blood samples
collected by the herd’s veterinary practitioner, we calculated, for each
calendar month in 2015, the number of young stock still in their birth
herd for each of the two recommended age classes: i) those between 6
and 12 months; and ii) those between 9 and 18 months. Using these
data, for each month of 2015 we identified those herds with ≥10 an-
imals available for serological testing in at least one of the age classes.
As we did not have any information on the management structure of
each herd, costs for serology were calculated under 3 different as-
sumptions about the relationship between the number of cows (female
animals which had produced a calf) in the herd on 30 th June 2015 and
the number of distinct management groups, with a sample of 10 ani-
mals tested from each management group. In our opinion, the three
assumptions covered the plausible extremes for management group size
in both dairy and beef herds in Ireland: i) all members of the herd
managed as one group and ii) one management group per 50 cows, as
well as iii) an intermediate value of one management group per 100
cows. We will refer to these as M∞, M50 and M100, respectively. For
most of our analysis, we assumed a combined sampling and test cost for
serology of €7.66 per animal, in accordance with information provided
by investigations conducted by AHI. Herd owners are required to meet
the test cost themselves. We did not include the costs of submitting
either tissue tag samples or blood samples to a laboratory. We assumed
that the effectiveness of the two methods for eradication of BVD in
Ireland was similar, as shown in modelling work described in Thulke
et al. (2018).
We also wanted to examine how the results of these analyses would
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vary according to the enterprise type (beef, dairy or mixed) of the herd.
Following Good et al. (2009) and Tratalos et al. (2017), we classifed
Irish cattle herds as being of beef or dairy enterprise type if ≥66% of
their stock were from beef or dairy breeds, respectively, calculated
using their combined end of year herd profiles for 2014 and 2015. All
other herds were classified as ‘mixed’, except a few herds which had no
stock at the end of the year in both 2014 and 2015: these were classified
as ‘unknown’. Breed type in the AIM system is based on breed of the
sire.
3.2. Comparison between herds
Using these data we compared: i) how the number of herds with
sufficient young stock to supply a sample for serological investigation
varied by test-month (in 2015) and enterprise type, ii) how potential
savings in testing costs, and the number of herds that would achieve
reduced testing costs following a switch to serology, would vary by
month, enterprise type and management group size (M∞, M50 and
M100), iii) the distribution of these reduced costs across herds, and v)
how potential testing costs varied with the number of cows in each
herd.
As we have already described, we made a number of assumptions in
this study on matters such as the cost per animal, sample size and the
age of sampled animals for serology. Amongst these, we were least
certain of the cost per animal for serology, recognising that these might
reduce as test volumes grow, or (less likely) increase due to unknown
factors. We therefore examined how costs for serology might affect i)
the number of herds which would potentially benefit from a switch to
serology, ii) total reduced testing costs if these herds were to switch and
iii) savings per herd in those herds which would achieve the largest
reduction in costs. This was done by means of a Visual Basic for
Applications (VBA) macro which calculated each of these 3 values at
increments of 0.1 Euro cent at testing costs between €2 and 10 per
animal, for the same 3 management group sizes used previously.
4. Results
4.1. Herds with sufficient young stock for serology
There were 78,380 herds which produced calves in 2015, consisting
of 59,196 beef, 14,247 dairy, 4880 mixed and 57 of unknown breed
type. These herds had 2,322,989 cows as of 30th June 2015, of which
998,151 were in beef, 1,117,120 were in dairy, 207,303 were in mixed
and 415 were in unknown herd types. 41,606 herds had ten or more
young stock in at least one of the two age classes examined (6–12 or
9–18 months of age) in at least one month of the year. Of these, almost
all (40,759) had sufficient young stock in the younger, 6–12 month,
category and most (34,663) also in the older category. The months
between September and April furnished the most herds with sufficient
young stock. Dairy herds were much more likely to have sufficient
young stock than beef (Fig. 1).
4.2. Herds with both sufficient young stock and a financial incentive to
choose serology under 3 different management scenarios
The number of herds which both i) contained sufficient young stock
for serological testing, and ii) would achieve a reduction in testing costs
from a switch to serology also varied by enterprise type and month of
the year when testing would be conducted, under each of the three
management group size variants (Fig. 2). Total potential savings were
for all months much greater for the dairy than beef sector and fewer
beef than dairy herds could reduce costs by switching to serology. This
was true even though beef herds greatly outnumbered dairy, a reflec-
tion of larger herd sizes amongst the latter. The largest number of herds
would achieve reduced costs in October, with 19,712 (25%) doing so
under M∞, 19,686 (25%) under M100 and 16,470 (21%) under M50.
Each month from September to March showed only slightly lower
percentages than October but there was a pronounced dip during May
to August, reflecting the larger number of herds lacking a large enough
sample of homebred young stock during these months. October was
also the sampling month for which the greatest total savings could be
realised: testing costs could be reduced by over €2.1 million under M∞
and €1.8 million under M100, and by approximately €0.8 million under
M50.
4.3. Reduced costs for individual herds
All further investigations were conducted under the assumption that
testing would take place in October, as more herds could potentially
benefit from a switch to serology if testing took place then. Fig. 3 shows
how savings would be distributed across the national herd, at an in-
dividual herd-level, if herds with a suitable number of young stock were
able to switch to serology (and assuming that only herds able to benefit
financially would do so), both in terms of € saved per cow and summed
for the herd. Fewer than 10% of all Irish herds would save more than
€1.42 per cow under M∞, €1.27 under M100 and €0.59 under M50.
Similarly, fewer than 10% of all Irish herds would save more than €99
each year in total under M∞, €96 under M100 or €36 under M50.
Amongst those herds that would save, the median amount saved would
be €73.4 per year under M∞ and M100, and €34.3 under M50.
4.4. Reduced costs by number of cows in the herd
The variability in potential savings for individual herds is shown in
Fig. 4, which plots the relationship between the number of cows in the
herd and reduction in testing costs if all herds which had a suitable
sample of young stock for serology were to use it (irrespective of
whether they would achieve reduced costs). Many of the smaller herds
would face larger costs using serology than tissue-tag testing. As might
be expected, given that testing costs for tissue-tag testing are a function
of the number of calves produced, the relationship between the number
of cows in the herd and the potential reduction in costs was found to be
positive.
4.5. Impact of changes in serology: cost-sensitivity analysis
Analysis of the effect of varying costs for serology (Fig. 5) showed
that overall costs varied between €3.6 million at the lowest serological
testing cost (€2) under M∞ to €0.24 million at the highest cost (€10)
under M50 (Fig. 5a). The effect of the number of management groups
tested (M∞, M50 or M100) on potential savings from switching to
serology was much more evident at higher testing costs (Fig. 5). This
was particularly true when the number of herds benefitting from
switching was measured (Fig. 5b), where it was found that the number
of groups made little difference at serology costs of less than €6 per
sample. At the lowest cost, €2, almost all herds which were able to
supply enough (10) appropriately aged young stock for serology would
achieve lower testing costs if they switched, as the cost per animal
tested would be lower than for tissue-tag testing (Fig. 5b). At serology
costs of less than €5, most herds with more than 50 cows (and thus> 1
management group under M50) would face lower testing costs using
serology, and therefore the number of herds which would benefit from
a switch was found to be only slightly lower under M50 than M∞
(Fig. 5b). Restricting this analysis to the 10th percentile of herds which
could potentially save the most from switching showed very little dif-
ference between the M50 and M100 scenarios, but that potential sav-
ings were much higher for these groups than for the M50 group, par-
ticularly as the assumed cost of serology testing increased (Fig. 5c).
However, Fig. 5c reveals that for 90% of all Irish herds the savings from
a strategy switch would be<= €155 per herd even under the most
extreme assumption that costs per test for serology would be lower than
for tag testing.
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5. Discussion
Using BVD as an example, the objective of our study was to estimate
the expected financial impact of changing an animal health interven-
tion strategy on the individual beneficiary. Only with this information
can we make informed decisions on the suitability of differing control
options in a programme driven by individually acting agents. We used a
three-stage method which might also be used for other diseases and
interventions, including: i) evaluating herd-level eligibility to partici-
pate in each strategy using annual stocking and production data, ii)
estimating costs, both industry wide and per individual production unit
i.e. cattle herd, summed for the unit and per individual animal (calving
cow in our example), and iii) examining variability in the distribution
of individual net benefits including grouping of beneficiaries into per-
centiles according to the net benefit accrued.
This method has allowed us to compare the herd-level costs of
tissue-tag testing of all newborn calves in a herd versus cohort-based
sampling of young stock for serological testing. Assuming our best es-
timates of the testing costs of both techniques, we have found that total
savings across the Irish cattle industry would be approximately €2.1
million, which is substantial compared to the current annual testing
budget of about €9 million; although it is small relative to the estimated
annual costs of BVD of €102 million before the eradication programme
was commenced (Stott et al., 2012). BVD control in Ireland is an in-
dustry-funded initiative designed to benefit its individual members.
Therefore, we believe that the benefits per individual participant in a
strategy change is more useful information than the total expected
gains. Only 25% of herds would face reduced testing costs if they
switched to serology, irrespective of what assumptions we made about
the number of management groups; and, depending on the number of
such groups per herd, as few as 2.3% of all Irish herds would save more
than €1 per cow, or €100 in total (Fig. 3). In general, dairy herds would
benefit more from a change to serology than beef herds, which reflects
the fact that dairy herds are typically larger than beef herds in Ireland.
We have found that sampling during the period September to March
would maximise the number of herds with a sufficiently large sample of
young stock for serological testing. We chose October for detailed
analysis as this was the month in which most savings could be made if
all serological testing were conducted then, and on the assumption that
it would not be practicable to have sampling dates tailored to each
herd. However, we did find that an additional 14.6% of herds would
have a sufficiently large sample for serological testing if the sampling
month could be tailored to each herd, rather than required to be
October (compare Fig. 1. October – All herds with Fig. 1. Any month –
All herds). This seasonality may be a reflection of the seasonal nature of
cattle breeding in Ireland, where predominantly grass-based production
systems biases the calving profile to the spring (DAFM, 2016), com-
bined with common practices such as selling male calves from dairy
herds in their first month of life and selling weaned beef calves in the
autumn.
Fig. 1. Percentage of herds with sufficient (10) young
stock for serological testing in each month of 2015, by
herd type (beef, dairy, mixed). Data for ‘Any’ month shows
the percentage of herds which would have a large enough
sample if the month of testing could be tailored to each
herd. The section of each bar shown in bold represents
those with sufficient animals in the 6–12 month cohort.
The pale section shows the number of additional herds
which would be eligible if the sample could also be taken
from a 9-18 month cohort. Separate information is shown
for beef and dairy herds and for all herds (including mixed)
considered together.
Fig. 2. The number of herds (right-hand axis) with a suitable sample of young stock in 2015 which would reduce testing costs by switching to serology (darker bars)
and the total annual reduction (left hand axis) in these costs which would be made if these herds were to switch (pale bars), for beef, dairy and mixed herds, by month
in 2015.
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We have utilized a number of assumptions in our analysis which
should be borne in mind when interpreting the results. One is that herds
need to be able to supply a sample of 10 animals of appropriate ages if
serology is to be an option for them. In the scientific literature, the
number of animals per management group required for serological
testing varies between 5 and 19 (e.g. Pillars and Grooms, 2002; Hanon
et al., 2016; see also Humphry et al., 2016). The BVDTWG re-
commendation regarding sampling is based on the strategic require-
ment to provide sufficient sensitivity and specificity at the herd-level,
which, used with a cut-point of two positive test results, requires 10
blood tests per management unit (Jordan and McEwen, 1998). While
smaller sample sizes and a cut point of 1 would reduce immediate costs,
the associated reduction in HSp would increase costs from follow up
testing and would also undermine confidence in the surveillance
strategy. In theory, herds could be allowed to test fewer young stock if
10 were not available. While this strategy could be used in herds where
fewer than 10 calves are born each year, it will not be less costly than
tissue tagging, based on the higher unit cost of serology (approximately
three-fold) and the small number of animals being tested. It would not
be appropriate in those herds where most of the young stock have been
sold before reaching the testing age for serology (see Tratalos et al.,
2017).
We also assume that herds should be able to supply these sampled
animals either from a 6–12 month or 9–18 month cohort. Again, the age
ranges stipulated vary between published studies, and we have chosen
these two ranges as the most typical, and able to fit the production
systems of most Irish herds. Making the age criteria wider (for example,
allowing the sampled animals to come from the entire age range of
6–18 months) or narrower (for example, allowing only the 9–18 month
age group, avoiding the possibility of interference from MDA) might
have some impact on our results. In some cases the testing of older
animals which had remained in the herd since the last herd test and had
previously tested negative might also be possible. However, it should be
borne in mind that herds with fewer than 10 young stock in both of the
two age cohorts considered in this study would also usually produce
fewer than 30 calves, and would therefore face lower costs for tissue-tag
testing at €2.50 per calf than serology at €7.66 per calf even if serology
were an option for them. We have also assumed that all young stock
tested should be homebred stock, to avoid positive tests due to infection
in previous herds.
We have assumed a cost of €2.50 per animal for tissue-tag testing,
which the current cost offered to NHS herds. In contrast, our estimate of
€7.66 for serology, used for most of the analyses, is a predicted cost
based on a survey of designated laboratories and expert opinion within
the TWG. It assumes that sera will be tested individually, as no Irish
laboratories are currently designated for testing of pooled sera, al-
though pooling has been used elsewhere (Løken and Nyberg, 2013;
Norström et al., 2014; Muñoz-Zanzi et al., 2000). This lack of certainty
is the reason we conducted the cost of serology to a sensitivity analysis
(Fig. 5).
We assume that sampling would be conducted in a single month of
the year. Although this is probably a simplification, we believe that it
represents a good approximation to the reality in Ireland where, given
the predominantly spring-based calving patterns, serology would be
conducted during a single time period in the autumn.
It should be emphasised that our analysis only considers the direct
costs of the two surveillance strategies, i.e. laboratory costs and pro-
fessional fees for sample taking. However, other costs might need to be
considered to capture the full economic costs of the two systems. For
example, postage costs are not included in the tissue-tag testing or
Fig. 3. The distribution of € saved per herd (left hand figure) among the 78,380 breeding herds in Ireland, and per cow in these herds, if all those herds with a
suitable sample of young stock and able to benefit financially were to switch to serology, under 3 assumptions on the number of young stock management groups (see
legend). For a given value on the X-axis, the corresponding Y-axis value shows the number of herds which would save that amount or more.
Fig. 4. Net savings/loss versus the number of cows for each herd if all herds with a suitable sample of young stock were to switch to serology. A linear trend line is
shown for each plot as well as the Pearson regression equation used to generate it.
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serological analyses, and costs of a veterinary visit (as opposed to a
sampling fee) are not considered for serology on the assumption that
the sampling can be carried out in conjunction with another visit.
Furthermore, we did not consider additional costs of PI identification
and removal for herds identified as positive under serological testing
(although there would be relatively few of these). In both cases, in-
clusion of these costs would further reduce the cost-effectiveness of the
serological alternative and the number of herds for which it would be
cheaper than tag testing.
We conducted our analyses on the assumption that young stock
management groups sizes would vary between one group per 50 cows
and one group for the whole herd (irrespective of herd size), and as-
sumed that the number of management groups would be determined
purely by the number of calving cows. In reality, group sizes would
differ between herds and may be determined with respect to factors
other than the number of animals - for example, males are commonly
separated from female calves in dairy herds. However, we believe the
three management group sizes we consider (M∞, M100 and M50) cover
a plausible range for most Irish herds.
We have made 2 further assumptions which are less important than
those discussed above but should nevertheless be borne in mind. Firstly,
we have calculated costs per cow by dividing total testing costs per herd
by the number of cows in that herd on 30th June. In the vast majority of
Irish herds, the mid-year number of cows in the herd should be a good
proxy for the size of the herd’s breeding stock for a given year.
However, the possibility of in- and out-movements mean that this might
not always be the case, and this should be borne in mind when ex-
amining the information shown in Fig. 3 (especially outliers for Euros
saved per cow) and Fig. 4 (all outliers). Secondly, in all herds where we
estimate i) that there were sufficient (10) young stock for serology and
ii) that, based on the number of cows in the herd on 30th June, there
was more than one management group, we have assumed that in these
herds there would also be sufficient (10) young stock in each group –
this may not always be the case, for example where there has been a lot
of selling of young stock or where the number of cows in the herd has
been recently increased.
Our analysis suggests that, before eradication is achieved, ser-
ological testing may only be practicable and cost effective for a min-
ority of herds in Ireland, particularly in the beef sector, where herds
often contain relatively few animals. In addition to costs, there are
other considerations which argue for the continuation of tissue-tag
testing. Firstly, if serology were to replace tissue-tag testing, tracing of
PIs would be harder to achieve, as many may have moved from their
birth herd before serological testing is conducted (see Tratalos et al.,
2017, for an analysis of Irish calf movements), a problem which has
been identified in the Swiss programme after making a switch from
tissue-tag testing to serology and bulk milk sampling (Schwermer and
Di Labio et al., 2016). Secondly, tissue-tag testing has been shown to be
effective in reducing the number of PIs born each year in Ireland and is
expected to result in eradication of BVD there; it would therefore in-
troduce unnecessary risk to switch to a different approach in the later
stages of the programme. Thirdly, a mixed tissue-tagging / serology
programme would be likely to bring about further inefficiencies caused
by trying to integrate the two approaches. Finally, the analysis did not
consider secondary market effects due to changes in the number of tag
tests conducted or the impact of other infections that could undermine
our confidence in the results of serological testing e.g. border disease
virus (BDV) circulation (Kaiser et al., 2017).
It is recognised that serological surveillance will have an important
role to play after eradication has been achieved, when the primary
purpose will be to provide early warning of reintroduced infections
rather than prompt detection of PI births. In this context, many of the
limitations identified here will be less important. There will be greater
flexibility in the ages of animals sampled, with the confounding effect
in younger calves of maternally derived antibodies being greatly re-
duced, while older animals can be sampled, increasing the numbers
available per herd, reducing the impact of sale of young stock and fa-
cilitating greater flexibility in the timing of sampling. In addition, other
serological surveillance strategies, particularly the use of bulk tank milk
testing, will become more useful as seroprevalence falls.
As other countries seek to eradicate BVD from their national herd,
they should take these results into account when evaluating alternative
surveillance strategies. In particular, the uneven distribution of benefits
amongst herds, with many smaller herds facing higher testing costs if
they were compelled to use serology, highlights the fact that there may
be losers as well as winners from any switch. In general, the larger the
herd and the fewer its management groups the more cost-effective
serology becomes as a surveillance method. Furthermore, we believe
that the general approach here is more widely applicable to other dis-
eases.
Fig. 5. The effect of testing costs for serological surveillance for BVD on a) the
total annual reduction in costs from a switch to serology in all herds which both
i) had a suitable sample of young stock in 2015 and ii) would reduce costs by
switching; b) how many herds would meet these criteria; and c) the reduction in
costs per herd which would be experienced by a herd at the 10th percentile of
savings. The grey vertical line is at €7.66, the assumed most likely testing cost.
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6. Conclusions
An examination of benefits at the herd level has shown the majority
of Irish cattle herd owners would not benefit financially from a switch
to serological testing for BVD before the disease is eradicated in Ireland,
with few, generally very large, herds benefitting substantially. In the
light of this, and given the risks involved in modifying an existing
successful eradication programme, we believe the use of serology in
BVD monitoring in Ireland should not be taken up until eradication has
been achieved. This analysis has shown the importance of looking at the
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